Not Yet Recruiting PHASE1 INTERVENTIONAL 2-arm NCT07044765

A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study

An Open-label, 2-arm, Single-sequence, Fed, Single Oral Dosing, Crossover Clinical Trial to Evaluate Safety and the Pharmacokinetics Between Dapagliflozin, Linagliptin and Metformin in Healthy Adult Subjects

Sponsor: AJU Pharm Co., Ltd.

Conditions Type2 Diabetes Mellitus

Interventions Comparator 1 Comparator 2 Test Drug

Updated 2 times since 2025 Last updated: Jun 26, 2025 Started: Aug 31, 2025 Primary completion: Nov 30, 2025 Completion: Nov 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Type2 Diabetes Mellitus and is currently actively recruiting participants. AJU Pharm Co., Ltd. leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.